1,2,4-Triazolo-[1,5-a]pyridine HIF Prolylhydroxylase Domain-1 (PHD-1) Inhibitors With a Novel Monodentate Binding...

Area of Science:

• Medicinal Chemistry
• Enzyme Inhibition
• Structural Biology

Background:

• Hypoxia-inducible factor prolylhydroxylase domain-1 (PHD-1) is a key regulator of cellular response to hypoxia.
• PHD-1 inhibitors are of therapeutic interest for various diseases, including anemia and cancer.
• Developing selective and potent PHD-1 inhibitors remains a significant challenge.

Purpose of the Study:

• To identify and characterize novel inhibitors of the PHD-1 enzyme.
• To elucidate the binding mode of these inhibitors using X-ray crystallography.
• To optimize inhibitors for improved potency and pharmacokinetic properties.

Main Methods:

• Structure-based drug design and synthesis of benzonitrile-based compounds.
• Enzyme inhibition assays to determine potency against PHD-1.
• X-ray crystallography to determine the co-crystal structure of inhibitors bound to PHD-1.
• Physicochemical and pharmacokinetic profiling of optimized compounds.

Main Results:

• Identification of 4-{[1,2,4]triazolo[1,5-a]pyridin-5-yl}benzonitrile derivatives as potent PHD-1 inhibitors.
• X-ray crystallography revealed a novel binding mode involving a unique monodentate interaction of the triazolo N1 atom with the active site Fe2+ ion.
• The benzonitrile moiety forms a key hydrogen bond with the Asn315 residue.
• Further optimization yielded compounds with favorable physicochemical and pharmacokinetic profiles.

Conclusions:

• The identified benzonitrile-based compounds represent a novel class of PHD-1 inhibitors.
• The elucidated unique binding mode provides a valuable template for future inhibitor design.
• These potent inhibitors with good drug-like properties warrant further investigation for therapeutic applications.